Indian biopharmaceutical company Biocon Limited (NSE:BIOCON) is seeking a partner to test generic versions of Novo Nordisk's (CPH:NOVO-B) diabetes drug Ozempic and weight loss treatment Wegovy in China, Reuters reported on Thursday.

An unnamed senior executive told the news agency that Biocon is looking for a Chinese partner for clinical trials on patients in order to sell the drug in China.

Biocon is aiming to launch generic versions of the drugs globally.

Patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, is due to expire in China in early 2026.